Ou, S. I. (2011). Crizotinib: A novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Dove Medical Press.
シカゴスタイル引用形Ou, Sai-Hong Ignatius. Crizotinib: A Novel and First-in-class Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Anaplastic Lymphoma Kinase Rearranged Non-small Cell Lung Cancer and Beyond. Dove Medical Press, 2011.
MLA引用形式Ou, Sai-Hong Ignatius. Crizotinib: A Novel and First-in-class Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Anaplastic Lymphoma Kinase Rearranged Non-small Cell Lung Cancer and Beyond. Dove Medical Press, 2011.
警告: この引用は必ずしも正確ではありません.